Aquestive Therapeutics AQST 深 沪
等待开盘 09-30 09:30:00 美东时间
4.67
-0.080
-1.68%
华盛通- 最 高4.75
- 今 开4.70
- 成交量 170.84万股
- 最 低 4.55
- 昨 收 4.75
- 总市值 5.86亿
- 52周最高 7.55
- 市盈率 静 --
- 换手率 1.36%
- 52周最低 2.93
- 委 比 -96.36%
- 总股本 1.26亿
- 历史最高 20.696
- 量 比 0.80
- 振 幅 4.21%
- 历史最低 0.618
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aquestive Therapeutics Adds Veteran Executive to Board
Aquestive Therapeutics ( ($AQST) ) has provided an update. On September 29, 202...
09-29 19:49
Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment
Aquestive Therapeutics Inc. (NASDAQ:AQST) on Thursday said it has officially resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm. FDA Resubmission The sublingual film aims to treat severe Type I allergic reactions, including life-threatening anaphylaxis. The re...
09-17 23:40
Aquestive resubmits Anaphylm NDA, advancing allergy treatment
An announcement from Aquestive Therapeutics ( ($AQST) ) is now available. On Se...
09-17 19:28
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film to the FDA, following positive results from human factors and pharmacokinetic studies announced in August 2026. The resubmission aims to address the FDA's Complete Response Letter issued in January 2026, which requested additional studies on packaging, administration, and pharmacokinetics. Anaphylm is designed for rapid treatment...
09-17 11:00
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive Therapeutics announced that its management team will participate in four investor conferences in September 2026. These include the 2026 Wells Fargo Healthcare Conference on September 8th, the Cantor Healthcare Conference with a fireside chat at 3:20 pm ET on September 9th, Citi’s 2026 Biopharma Back to School Summit on September 10th, and the H.C. Wainwright 27th Annual Global Investor Conference with a presentation at 9:00 am ET on Sep...
09-01 11:00
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains $10 price target.
08-24 18:07
Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress
Aquestive Therapeutics, Inc. (($AQST)) has held its Q2 earnings call. Read on f...
08-21 08:25
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $50.584 million estimate.
08-12 04:01
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual film
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual film
08-10 21:21
